Blacksmith Medicines

Executive Summary

Blacksmith Medicines is a San Francisco-based biotechnology company founded in 2019, dedicated to developing small molecule inhibitors targeting human metalloenzymes. Its proprietary platform leverages medicinal bioinorganic chemistry to address diseases driven by metal-dependent enzymes, an area historically challenging for drug discovery. The company's approach enables the design of potent and selective inhibitors for metalloenzymes implicated in various diseases, including cancer, inflammation, and infectious diseases. As a private, pre-revenue biotech, Blacksmith Medicines is at an early stage, focusing on platform validation and advancing its pipeline toward preclinical development. The company's unique focus on metalloenzymes positions it to address unmet medical needs, but it remains dependent on continued funding and scientific progress to reach clinical milestones.

Upcoming Catalysts (preview)

• Q4 2026Lead Optimization and IND-Enabling Studies for Lead Program30% success
• Q2 2026Series A Financing Round50% success
• Q3 2026Publication of Platform Validation Data in Peer-Reviewed Journal60% success